Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Research and Markets
DUBLIN, Apr. 03, 2014 /PRNewswire/ --
Research and Markets
) has announced the addition of the
report to their offering.
A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective
Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.
Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.
The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.
This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.
Benefits from the report:
Key Topics Covered:
1. Executive Summary
3. The T-Cell Receptor
4. TCR Fusion Proteins
5. TCR-Like (TCRL) Antibodies
6. TCR-Transfected T-Cells
7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells
8. Tumor-Infiltrating Lymphocytes (TILs)
9. Opportunity Analysis for TCR-based Products and Technologies
11. Corporate R&D Pipelines
For more information visit http://www.researchandmarkets.com/research/gw6znv/the_engineered
Laura Wood , +353-1-481-1716, firstname.lastname@example.org
©2012 PR Newswire. All Rights Reserved.